User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.

Primary tabs

Gerkens, Sophie [UCL] Nechelput, M. Annemans, L. Peraux, B Mouchart, Michel [UCL] Horsmans, Yves [UCL] Beguin, Claire [UCL]

According to the current guidelines, it is advised not to treat patients with mild chronic hepatitis C. However, discussions as to giving immediately a treatment (direct treatment) to these patients have started and the incremental cost-effectiveness ratio (ICER) of such strategy is still unknown. The aim of this study was to estimate, in the health care payer perspective, the ICER of a direct treatment of patients with mild chronic hepatitis C in comparison with the strategy of monitoring these patients and treat them when the disease will progress to the state of moderate chronic hepatitis. The treatment assessed was the current standard treatment composed of pegylated interferon alpha-2a and ribavirin. At the beginning of the study, patients were aged 45. Long-term economic and clinical outcomes over a 30-year period were predicted using a Markov simulation model. Data were obtained from published literature. Monte Carlo simulations were used to determine 95% confidence intervals of results. The ICER of a direct treatment with PEG IFN alpha-2a and ribavirin is 23,046 euro/QALY (CI 95% 3,882 euro-42,392 euro) for genotypes 1-4-5-6 and 4,631 euro/QALY (CI 95% 797 euro-7,881 euro) for genotypes 2-3. Sensitivity analysis shows that it is only in extreme circumstances related to the utilities that the ICER for genotypes 1-4-5-6 is unacceptably high for the society (>50,000 euro). Even though a direct treatment is more expensive, it gives the advantage of curing greater number of patients and of increasing quality-adjusted life-years (QALYs), implying that such strategy is generally cost-effective at a threshold of 50,000 euro/QALY.

Document type Article de périodique (Journal article) – Comparative Study, Journal Article
Access type Accès restreint
Publication date 2007
Journal information "Journal of viral hepatitis" - Vol. 14, no. 8, p. 523-36 (2007)
Peer reviewed yes
issn 1352-0504
Publication status Publié
Affiliations UCL - ESPO/COMU - Département de communication
UCL - (SLuc) Service d'hépato-gastro-entérologie
UCL - MD/MINT - Département de médecine interne
MESH Subject Antiviral Agents - economics - therapeutic use ; Belgium ; Computer Simulation ; Cost-Benefit Analysis ; Drug Costs ; Hepacivirus - growth & development ; Hepatitis C, Chronic - drug therapy - economics - virology ; Humans ; Interferon Alfa-2a - economics - therapeutic use ; Markov Chains ; Middle Aged ; Models, Econometric ; Polyethylene Glycols - economics - therapeutic use ; Quality-Adjusted Life Years ; Ribavirin - economics - therapeutic use
Links
  1. Shepherd J, Health Technol Assess, 4, 1 (2000)
  2. Van Damme P, Acta Gastroenterol Belg, 65, 78 (2002)
  3. 3F Renard, M Autier, and D Doumont . L'hepatite C en Belgique, comment ameliorer le depistage et la prevention ? Belgique: Ecole de sante Publique, Unite d'Education pour la sante, Serie de dossiers techniques CFB, Report No. 05-34, 27 pp.
  4. Delwaide J, Acta Gastroenterol Belg, 65, 233 (2002)
  5. Sullivan S. D., Jensen D. M., Bernstein D. E., Hassanein T. I., Foster G. R., Lee S. S., Cheinquer H., Craxi A., Cooksley Graham, Klaskala W., Pettit K., Patel K. K., Green J., Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C, 10.1111/j.1572-0241.2004.30286.x
  6. Annemans L, Acta Gastroenterol Belg, 67, 1 (2004)
  7. Alberti A, Hepatol Rev, 2, 19 (2005)
  8. Salomon J. A., Empirically Calibrated Model of Hepatitis C Virus Infection in the United States, 10.1093/aje/kwf100
  9. Michielsen P, Acta Gastroenterol Belg, 66, 15 (2003)
  10. Wong John B., Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis, 10.7326/0003-4819-133-9-200011070-00008
  11. Levine Robert A., Treating Histologically Mild Chronic Hepatitis C: Monotherapy, Combination Therapy, or Tincture of Time?, 10.7326/0003-4819-129-4-199808150-00010
  12. Drummond MF, Methods for the Economic Evaluation of Health Care Programmes (1997)
  13. Sonnenberg Frank A., Beck J. Robert, Markov Models in Medical Decision Making : A Practical Guide, 10.1177/0272989x9301300409
  14. Briggs Andrew, Sculpher Mark, An Introduction to Markov Modelling for Economic Evaluation : , 10.2165/00019053-199813040-00003
  15. Fried Michael W., Shiffman Mitchell L., Reddy K. Rajender, Smith Coleman, Marinos George, Gonçales Fernando L., Häussinger Dieter, Diago Moises, Carosi Giampiero, Dhumeaux Daniel, Craxi Antonio, Lin Amy, Hoffman Joseph, Yu Jian, Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, 10.1056/nejmoa020047
  16. Hadziyannis Stephanos J., Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C : A Randomized Study of Treatment Duration and Ribavirin Dose, 10.7326/0003-4819-140-5-200403020-00010
  17. Salomon Joshua A., Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population, 10.1001/jama.290.2.228
  18. Younossi Zobair M., Singer Mendel E., McHutchison John G., Shermock Kenneth M., Cost effectiveness of interferon ?2b combined with ribavirin for the treatment of chronic hepatitis C, 10.1002/hep.510300518
  19. Bennett William G., Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C, 10.7326/0003-4819-127-10-199711150-00001
  20. Sagmeister Markus, Wong John B., Mullhaupt Beat, Renner Eberhard L., A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C : , 10.1097/00042737-200105000-00004
  21. Sennfält K., Reichard O., Hultkrantz R., Wong J. B., Jonsson D., Cost-effectiveness of Interferon Alfa-2b With and Without Ribavirin as Therapy for Chronic Hepatitis C in Sweden, 10.1080/003655201750313414
  22. Siebert U, Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C, 10.1136/gut.52.3.425
  23. Kim W. Ray, Cost-Effectiveness of 6 and 12 Months of Interferon-α Therapy for Chronic Hepatitis C, 10.7326/0003-4819-127-10-199711150-00002
  24. Wong John B., Poynard Thierry, Ling Mei-Hsiu, Albrecht Janice K., Pauker Stephen G., , Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c, 10.1111/j.1572-0241.2000.2089_1.x
  25. Jusot J.F., Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients, 10.1093/eurpub/11.4.373
  26. Wong JB, Acta Gastroenterol Belg, 65, 110 (2002)
  27. Cleemput I, Recommandations provisoires pour les evaluations pharmacoeconomiques en Belgique (2006)
  28. Grieve R, Cost effectiveness of interferon   or peginterferon   with ribavirin for histologically mild chronic hepatitis C, 10.1136/gut.2005.064774
  29. Shepard DS, Health and Medicine, 2, 91 (1996)
  30. Blackmore C. Craig, Ramsey Scott D., Mann Frederick A., Deyo Richard A., Cervical Spine Screening with CT in Trauma Patients: A Cost-effectiveness Analysis, 10.1148/radiology.212.1.r99jl08117
  31. Roze Stéphane, Valentine William J., Evers Thomas, Palmer Andrew J., Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting, 10.1185/030079906x115531
  32. de Torres M, Ann Hepatol, 2, 5 (2003)
  33. McCabe Chris, Dixon Simon, Testing the Validity of Cost-Effectiveness Models : , 10.2165/00019053-200017050-00007
  34. Hammerschmidt Thomas, Goertz Anita, Wagenpfeil Stefan, Neiss Albrecht, Wutzler Peter, Banz Kurt, Validation of Health Economic Models: The Example of EVITA, 10.1046/j.1524-4733.2003.65241.x
Bibliographic reference Gerkens, Sophie ; Nechelput, M. ; Annemans, L. ; Peraux, B ; Mouchart, Michel ; et. al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.. In: Journal of viral hepatitis, Vol. 14, no. 8, p. 523-36 (2007)
Permanent URL http://hdl.handle.net/2078.1/11037